Sign Up for a Free Account
  • Updated 11.02.2020
  • Released 07.06.1999
  • Expires For CME 11.02.2023



Historical note and terminology

In 1998 the United States Food and Drug Administration approved modafinil as a wake-promoting agent (to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy). This was the first time in over 40 years such a drug was approved. In 2010 the European Medicines Agency withdrew the indication of modafinil for the treatment of obstructive sleep apnea, shift-work sleep disorder, and idiopathic hypersomnia.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660